# Jennifer A. Wargo

Source: https://onco.cc/people/jennifer-wargo/  
OnCo record `jennifer-wargo` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Surgeon-scientist who showed the gut microbiome shapes response to immunotherapy and led early neoadjuvant melanoma trials.

## Summary

Jennifer Wargo led the 2018 Science paper showing that gut microbiome composition predicts response to PD-1 blockade in melanoma patients, alongside parallel work from Gustave Roussy and Chicago that founded microbiome-directed immuno-oncology. She led one of the first randomised neoadjuvant immunotherapy trials in melanoma and co-leads the International Neoadjuvant Melanoma Consortium. Her laboratory now studies diet, fibre and microbiome modulation.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: melanoma; microbiome; neoadjuvant
- Role: Professor of Genomic Medicine and Surgical Oncology, MD Anderson Cancer Center
- Specialisms: Melanoma; Microbiome and immunotherapy; Neoadjuvant immunotherapy; Surgical oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Wargo%20JA%5BAuthor%5D%20microbiome%20melanoma

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- trials: [FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)](https://onco.cc/trials/fmt-pd1-refractory-melanoma-pitt/)

---
JSON: https://onco.cc/api/v1/entities/jennifer-wargo.json